
Solid Tumors with Specific Mutations
MGMT promoter hypermethylation positive
▼ 10572: A Phase 1 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774
DNA repair; PI3K/AKT; RAS/RAF/MEK
10371: A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
10528: Phase 1 study of the POLq inhibitor Novobiocin in BRCA-mutant and other DNA damage repair-deficient solid tumors
inactivating ATM mutations, amplification of MYC, mutation of FBXW7, CCNE1 amplification, SWI/SNF member mutation
10527: A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774
HER2-positive
10355: A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies
10358: Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
10495: Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations